MetabolicNot approvedEvidence tier: Animal Only

5-Amino-1MQ

Last updated October 21, 2026. Approval line checked October 21, 2026. No compounding source date is assigned.

FDA status

Not approved

Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.

FDA: Unapproved drugs

Evidence tier

Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 1/5. 35 PubMed citations indexed.

Products sold as "research use only" are not approved for human use. FDA warning.

5-Amino-1MQ in the literature

Small molecule NNMT inhibitor that increases NAD+ precursor availability and activates SIRT1-mediated metabolic pathways; reduces adipogenesis in preclinical models.

What the literature studies

Metabolic Optimization & Fat Loss

Evidence tier

Animal Only

Compounding record

Status not verified

Confidence
1/5

Regulatory record

Status not verified. No product-specific FDA primary source is recorded for this entry. FDA approval and compounding eligibility are not verified. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.

Regulatory source not verified; no checked date is assigned.

Entirely preclinical; no published human safety data; mechanism involves epigenetic pathways with unclear long-term consequences.

Questions

Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.

Short answer

5-Amino-1MQ is a small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor studied in obese mice for weight and metabolic effects; it is not a peptide, not FDA-approved, and has no published human clinical trials as of this check.

What it is

A membrane-permeable quinolinium NNMT inhibitor (often abbreviated 5-amino-1MQ or 5A1MQ), not a peptide hormone analog [R1]. It appears in peptide catalogs because of adjacent metabolic interest, which is why it is listed on peptidex.ai.

Legal / FDA status (as of Oct 27 2026)

Not FDA-approved for any use. Not an approved drug substance for compounding as a marketed obesity therapy. Sold online as a "research chemical" - identity, purity, and sterility of gray-market material are unverified. peptidex.ai does not sell it or link to sellers.

Human evidence

No completed, published human clinical trials of 5-amino-1MQ for obesity or metabolic disease were identified. Reviews of NNMT as a target state that NNMT-focused clinical trials have not been documented [R3].

Animal / lab evidence

  • Selective NNMT inhibitors including 5-amino-1MQ reduced body weight and white-adipose mass in diet-induced obese mice without reducing food intake in the reported study design [R1].
  • A later DIO-mouse study of 5A1MQ reported improved glucose/insulin measures and attenuated fatty-liver pathology over 28 days [R2].
  • Animal results are not evidence of clinical benefit or safety in people.

Risks and unknowns

Human safety, pharmacokinetics, and efficacy are unknown. Off-target and long-term effects are uncharacterized in humans. Product quality on the research market is unverified.

What's coming

NNMT remains an investigational metabolic target. No FDA approval pathway for 5-amino-1MQ was identified in this check.

Sources

  1. [R1] Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018;147:141-152. PMID 29155147
  2. [R2] Babula JJ et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab 2024. PMID 39161060
  3. [R3] Sun WD et al. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome. Front Pharmacol 2024. PMID 38919254

Last checked 2026-10-27

Education only. Not medical advice. No dosing guidance. peptidex.ai does not sell peptides or link to sellers.